# Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

> **NCT00734253** · PHASE2 · COMPLETED · sponsor: **NephroGenex, Inc.** · enrollment: 317 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** Pyridoxamine Dihydrochloride
- **DRUG:** Pyridoxamine Dihydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00734253
- **Lead sponsor:** NephroGenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2015-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734253, "Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00734253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*